🔎 Trials Near Me

Utama › Kanser Paru-paru Bukan Sel Kecil › Minnesota

Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Minnesota

69 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi di Minnesota.

Bandar di Minnesota

Teks kajian rasmi (Bahasa Inggeris)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Sanford Joe Lueken Cancer Center, Bemidji
  • Minnesota Oncology - Burnsville, Burnsville
  • Mercy Hospital, Coon Rapids
  • dan 16 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • Sanford Joe Lueken Cancer Center, Bemidji
  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Essentia Health - Deer River Clinic, Deer River
  • dan 6 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07293247

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #68, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05176483

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

  • Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06918132

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Health Partners Frauenshuh Cancer Center, Saint Louis Park
  • Health Partners Cancer Center at Regions Hospital, Saint Paul
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06172478

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Sanford Joe Lueken Cancer Center, Bemidji
  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Mercy Hospital, Coon Rapids
  • dan 12 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06498635

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  • Research Site, Rochester
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06996782

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Minnesota Oncology Hematology, Maple Grove
  • Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07361497

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Minnesota Oncology Hematology, PA, Burnsville
  • Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
  • Minnesota Oncology Hematology, PA, Coon Rapids
  • dan 7 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027), Minneapolis
  • Mayo Clinic - Rochester ( Site 0073), Rochester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Minnesota Oncology Hematology, P.A., Burnsville
  • Minnesota Oncology Hematology, P.A., Chaska
  • Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
  • dan 7 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07222566

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Mayo Clinic Rochester, Rochester
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04981119

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Minnesota Oncology Hematology, PA, Burnsville
  • Minnesota Oncology Hematology PA, Coon Rapids
  • M Health Fairview Cancer Clinic-Edina, Edina
  • dan 10 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University Of Minnesota, Minneapolis
  • Mayo Clinic Rochester, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07154290

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115), Minneapolis
  • Mayo Clinic - Rochester ( Site 0148), Rochester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06170788

Pan-tumor MRD Study

  • Mayo Clinic, Rochester
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • Minnesota Oncology - Burnsville, Burnsville
  • Cambridge Medical Center, Cambridge
  • Minnesota Oncology Hematology PA-Chaska, Chaska
  • dan 23 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT03191149

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06693336

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Duluth
  • Research Site, Rochester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Sites, Duluth
  • Clinical Study Site, Minneapolis
  • Clinical Study Site, Saint Paul
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06767514

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

  • Minnesota Oncology and Hematology PA, Minneapolis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05267626

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Masonic Cancer Center University of Minnesota, Minneapolis
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • USOR - Minnesota Oncology - Burnsville, Burnsville
  • Local Institution - 007-589A, Edina
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04613596

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06899126

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Mayo Clinic (Rochester), Rochester
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT04302025

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
  • HealthPartners Cancer Research Center, Saint Paul
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

  • Mayo Rochester, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07361562

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Rochester
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07291037

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146), Minneapolis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06422143

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • University of Minnesota Masonic Cancer Center, Minneapolis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07216105

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07027514

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT05245500

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

  • Mayo Clinic - Rochester, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT04913285

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • Research Site, Saint Paul
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06350097

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

  • Mayo Clinic-Rochester, Rochester
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06892548

A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer

  • Mayo Clinic in Rochester, Rochester
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06122064

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.